Skip to main content
Log in

Influence of Surface-Modifying Surfactants on the Pharmacokinetic Behavior of 14C-Poly (Methylmethacrylate) Nanoparticles in Experimental Tumor Models

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. The aim of this study was to investigate the different pharmacokinetic behavior of surface-modified poly(methylmethacrylate) (PMMA) nanoparticles.

Methods. The particles were 14C-labeled and coated with polysorbate 80, poloxamer 407, and poloxamine 908. Plain particles served as control particles. In vivo studies were performed in three tumor models differing in growth, localization, and origin. Particle suspensions were administered via the tail vein, and at given time animals were killed and organs were dissected for determination of PMMA concentration.

Results. For the PMMA nanoparticles coated with poloxamer 407 or poloxamine 908, high and long-lasting concentrations were observed in the melanoma and at a lower level in the breast cancer model. In an intracerebrally growing glioma xenograft, the lowest concentrations that did not differ between the tumor-loaded and tumor-free hemispheres were measured. Organ distribution of the four investigated batches differed significantly. For instance, poloxamer 407- and poloxamine 908-coated particles circulated over a longer period of time in the blood, leading additionally to a higher tumor accumulation. In contrast, plain and polysorbate 80-coated particles accumulated mainly in the liver. The strong expression of vascular endothelial growth factor and Flk-1 in the melanoma correlated with high concentrations of PMMA in this tumor.

Conclusion. The degree of accumulation of PMMA nanoparticles in tumors depended on the particle surface properties and the specific growth differences of tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. Y. Matsumura and H. Maeda. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 6:6387-6392 (1986).

    Google Scholar 

  2. H. Maeda and Y. Matsumura. Tumoritropic and lymphotropic principles of macromolecular drugs. CRC Crit. Rev. Ther. Drug Carrier Syst. 6:193-210 (1989).

    Google Scholar 

  3. L. W. Seymour. Passive tumour targeting of soluble macromolecules and drug conjugates. CRC Crit. Rev. Ther. Drug Carrier Syst. 9:135-187 (1992).

    Google Scholar 

  4. R. Duncan, S. Dimitijevic, and E. G. Evagorou. The role of polymer conjugates in the diagnosis and treatment of cancer. S.T.P. Pharma Sci. 6:237-263 (1996).

    Google Scholar 

  5. R. K. Jain. Delivery of molecular and cellular medicine to solid tumors. Microcirculation 4:1-23 (1997).

    Google Scholar 

  6. P. Beck, J. Kreuter, R. Reszka, and I. Fichtner. Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumor models. J. Microencapsul. 10:101-114 (1993).

    Google Scholar 

  7. R. Reszka, P. Beck, I. Fichtner, M. Hentschel, J. Richter, and J. Kreuter. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-Melanoma-bearing mice. J. Pharmacol. Exp. Ther. 280:232-237 (1997).

    Google Scholar 

  8. S. D. Tröster, K. H. Wallis, R. H. Müller, and J. Kreuter. Correlation of the surface hydrophobicity of 14C-poly(methyl methacrylate) nanoparticles to their body distribution. J. Control. Release 20:247-260 (1992).

    Google Scholar 

  9. S. D. Tröster and J. Kreuter. Influence of the surface properties of low contact angle surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles. J. Microencapsulation 9:19-28 (1992).

    Google Scholar 

  10. U. Schröder and B. A. Sabel. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 710:121-124 (1996).

    Google Scholar 

  11. J. Kreuter, R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674:171-174 (1995).

    Google Scholar 

  12. R. N. Alyautdin, D. Gothier, V. E. Petrov, D. A. Kharkevich, and J. Kreuter. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41:44-48 (1995).

    Google Scholar 

  13. R. N. Alyautdin, V. E. Petrov, K. Langer, A. Berthold, D. A. Kharkevich, and J. Kreuter. Delivery of loperamid across the blood-brain barrier with polysorbate 80-coated poly-butyl-cyanoacrylate nanoparticles. J. Pharm. Res. 14:325-328 (1997).

    Google Scholar 

  14. J. Kreuter, U. Täuber, and V. Illi. Distribution and elimination of poly(methyl-2-14C-methacrylate) nanoparticle radioactivity after injection in rats and mice. J. Pharm. Sci. 68:1443-1447 (1979).

    Google Scholar 

  15. F. Brasseur, P. Couvreur, B. Kante, L. Deckers-Passau, M. Roland, C. Deckers, and P. Speiser. Actinomycin D adsorbed on polymethylmethacrylate nanoparticles: an increased efficiency against an experimental tumor. Eur. J. Cancer 16:1441-1445 (1980).

    Google Scholar 

  16. P. Couvreur, L. Grislain, and V. Lenaerts. Biodegradable polymeric nanoparticles as a drug carrier for antitumor agents. In P. Guiot and P. Couvreur (eds.), Polymeric Nanoparticles and Microspheres, CRC Press, Boca Raton, 1986.

    Google Scholar 

  17. D. Sharma, T. Chelvi, J. Kaur, K. Chakravorty, T. De, A. Maitra, and R. Ralham. Novel Taxol® formulation: polyvinylpyrolidone nanoparticle-encapsulated Taxol® for drug delivery in cancer therapy. Oncol. Res. 8:281-286 (1996).

    Google Scholar 

  18. E. M. Gipps, R. Arshady, J. Kreuter, P. Groscurth, and P. P. Speiser. Distribution of polyhexylcyanoacrylate nanoparticles in nude mice bearing human osteosarcoma. J. Pharm. Sci. 75:256-258 (1986).

    Google Scholar 

  19. B. Endrich, H. S. Reinhold, J. F. Gross, and M. Intaglietta. Tissue perfusion inhomogeneity during early tumor growth in rats. J. Natl. Cancer Inst. 62:387-395 (1979).

    Google Scholar 

  20. J. Kreuter. Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet. 3:253-256 (1994).

    Google Scholar 

  21. S. E. Dunn, A. G. A. Coombes, M. C. Garnett, S. S. Davis, M. C. Davies, and L. Illum. In vitro cell interaction and in vivo biodistribution of poly (lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers. J. Control. Release 44:65-76 (1997).

    Google Scholar 

  22. J. E. O'Mullane, P. Artursson, and E. Tomlinson. Biopharmaceutics of microparticle drug carriers. Ann. NY Acad. Sci. 507:100-140 (1987).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lode, J., Fichtner, I., Kreuter, J. et al. Influence of Surface-Modifying Surfactants on the Pharmacokinetic Behavior of 14C-Poly (Methylmethacrylate) Nanoparticles in Experimental Tumor Models. Pharm Res 18, 1613–1619 (2001). https://doi.org/10.1023/A:1013094801351

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1013094801351

Navigation